TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22289557
Drug: Fentanyl priming
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl priming dose
Study: 16757523
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid treatment
Study: 15282657
Drug: Anti-PF4/heparin antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PF4/heparin antibodies
Study: 11159092
Drug: Power injection
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Power injection through central venous catheter
Study: 9285658
Drug: Ibutilide (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide (0.01 then 0.002 mg/kg)
Study: 9285658
Drug: Ibutilide (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide (0.02 then 0.004 mg/kg)
Study: 9285658
Drug: Ibutilide (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide (0.03 then 0.006 mg/kg)
Study: 3828181
Drug: Regular timed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular timed injections of bupivacaine (0.5%, 0.375%, 0.25%)
Study: 3828181
Drug: On demand
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On demand injections of bupivacaine (0.5%, 0.375%, 0.25%)
Study: 3828181
Drug: Regular top-up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular top-up injections
Study: 31355467
Drug: Pevonedistat in
Normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pevonedistat in combination with azacitidine
Study: 29508904
Drug: Low vitamin
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low vitamin B12 status (<234 pmol/L; 317 pg/mL)
Study: 29508904
Drug: Elevated homocysteine
Normalized name: mecysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated homocysteine (>15 µmol/L)
Study: 23948685
Drug: Intensive activity-based
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive activity-based therapy applied during the critical period (younger than 2 years)
Study: 23948685
Drug: Previous activity-based
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous activity-based therapies
Study: 16622438
Drug: Adjuvant oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant oral capecitabine
Study: 16622438
Drug: Adjuvant intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant intravenous 5-FU/LV
Study: 12630027
Drug: Interferon and
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon and amantadine hydrochloride (100 mg orally daily) for 26 weeks
Study: 12630027
Drug: Interferon alone
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alone (natural interferon‐beta 6 MU daily for 6 weeks and thrice‐a‐week for 20 weeks) for 26 weeks
Study: 1673324
Drug: Esmolol (less
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (less than or equal to 24 mg/min)
Study: 7060824
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg triamcinolone hexacetonide (TH)
Study: 7060824
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg methylprednisolone (MP)
Study: 7060824
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg betamethasone (BM)
Study: 16170078
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human IL-1 receptor antagonist (rhIL-1ra)
Study: 12049374
Drug: Metoprolol or
Normalized name: metoprolol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol or Propranolol (maximal tolerated dose, 28 patients, group A, 86±23 vs 98±29 mg/d)
Study: 12049374
Drug: No pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pharmacological therapy (28 patients, group B)
Study: 12049374
Drug: No pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pharmacological therapy (group B)
Study: 12049374
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (beta-blockers)
Study: 9508205
Drug: Granisetron 3
Normalized name: granisetron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 3 mg i.v. plus dexamethasone 10 mg i.v. prechemotherapy followed by granisetron 1 mg orally at 6 and 12 hours, then granisetron 1 mg orally and dexamethasone 8 mg orally twice daily on days 2 through 7
Study: 31711921
Drug: Etrasimod 1
Normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrasimod 1 mg
Study: 20546271
Drug: Supper (15-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supper (15-g carbohydrate dairy snack before bed)
Study: 15865113
Drug: Preoperative radiology
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiology (intravenous cholangiography or magnetic resonance cholangiography)
Study: 12848204
Drug: Protocol A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A: Fluid restriction, avoidance of routine sedation, higher doses of mannitol
Study: 12848204
Drug: Unrestricted fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unrestricted fluid supplementation, routine sedation, lower doses of mannitol (only when needed) for GCS ≤ 8
Study: 9202359
Drug: HMG‐CoA reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMG‐CoA reductase inhibitors
Study: 3327846
Drug: 400 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/kg body weight of i.v. IgG on 5 consecutive alternate days and subsequently after 15 days and monthly thereafter for up to six months
Study: 27550953
Drug: Lenalidomide 10
Normalized name: lenalidomide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 10 mg once daily for 12 weeks
Study: 11549103
Drug: Combined doses
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined doses of piperacillin and tobramycin
Study: 9549737
Drug: Late cannulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late cannulation (Group L)
Study: 26596627
Drug: Infliximab (IFX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (IFX), a single intravenous injection of 3 mg/kg
Study: 26596627
Drug: Placebo, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, a single saline serum injection
Study: 23945572
Drug: Simplified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simplified treatment regimens for severe infection
Study: 1512328
Drug: Alteplase (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (10 mg bolus, then 90 mg over 2 h) followed by heparin
Study: 1512328
Drug: Heparin (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (continuous infusion rate of 1,750 IU/h)
Study: 6240405
Drug: PN 200-110
Approvals — FDA: no, EMA: no, PMDA: no
Description: PN 200-110 (2.5 mg, 5.0 mg, 10.0 mg)
Study: 23250532
Drug: Local immunomodulator
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local immunomodulator (0.04% synthetic tetradecapeptide solution)
Study: 20462428
Drug: 42 g
Normalized name: PETROLATUM 42 g in 100 g TOPICAL OINTMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 42 g raw walnuts/d for 6 weeks
Study: 20462428
Drug: 21 g
Normalized name: Long's Lancets, 21 ga
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 g raw walnuts/d for 6 weeks
Study: 18765001
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone gel (90 mg, once daily)
Study: 18765001
Drug: Vaginal micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal micronized progesterone tablets (200 mg, three times daily)
Study: 11019474
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment (day care)
Study: 11019474
Drug: Inpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient treatment (hospital admission)
Study: 11019474
Drug: Overall acceptability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall acceptability of outpatient treatment
Study: 2334155
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of norfloxacin alone
Study: 2334155
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of norfloxacin 5 min after aluminum‐magnesium hydroxide (Maalox)
Study: 2334155
Drug: Maalox 2
Normalized name: Gas-X with Maalox 250 MG / 62.5 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maalox 2 h after 400 mg of norfloxacin
Study: 2334155
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of norfloxacin 5 min after calcium carbonate (Titralac)
Study: 2334155
Drug: Antacid administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid administration
Study: 31101323
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers (after excluding patients with prior myocardial infarction or heart failure)
Study: 28588686
Drug: Continuous renal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous renal replacement therapy (CRRT) for 24 hours
Study: 23995030
Drug: Pharmacotherapy (paroxetine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (paroxetine)
Study: 19210949
Drug: Brief cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive-behavioral therapy (CBT)
Study: 11052924
Drug: Retinyl palmitate
Normalized name: Retinyl palmitate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinyl palmitate (RP) 400000 i.u. administered intramuscularly to 6 patients
Study: 1341892
Drug: OK-432 (1KE
Approvals — FDA: no, EMA: no, PMDA: no
Description: OK-432 (1KE or 5KE) administered one or 3 times every other day
Study: 1341892
Drug: OK-432 (repeated
Approvals — FDA: no, EMA: no, PMDA: no
Description: OK-432 (repeated injections)
Study: 1341892
Drug: OK-432 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: OK-432 (doses more than 5 KE)
Study: 29480440
Drug: Weekly short-term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly short-term lotteries for 13 weeks
Study: 26995281
Drug: 12-month digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month digital health weight loss intervention including algorithm-generated tailored behavior change goals, self-monitoring via mobile technologies, daily self-weighing using a network-connected scale, skills training materials, 18 counseling phone calls with a Track coach, and primary care provider counseling.
Study: 10639654
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (verbal and written advice and exercises)
Study: 11540403
Drug: 5 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/70 kg d-methamphetamine
Study: 11540403
Drug: 10 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/70 kg d-methamphetamine
Study: 1858618
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (group I)
Study: 28292304
Drug: iCPR tool
Approvals — FDA: no, EMA: no, PMDA: no
Description: iCPR tool with academic detailing about strep pharyngitis and pneumonia diagnosis and treatment
Study: 28292304
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with academic detailing about strep pharyngitis and pneumonia diagnosis and treatment
Study: 27004425
Drug: GS-9190 single
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-9190 single dose
Study: 27004425
Drug: GS-9190 multiple
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-9190 multiple doses (8 days)
Study: 27004425
Drug: GS-9190 multiple
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-9190 multiple doses (4-6 months follow-up)
Study: 20190467
Drug: Risedronate monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate monotherapy (n=8)
Study: 20190467
Drug: Combined risedronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined risedronate and vitamin K(2) therapy (n=8)
Study: 20190467
Drug: Intravenous steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous steroid pulse therapy (n=6, group C)
Study: 15681523
Drug: Capecitabine (2,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (2,500 mg/m2/d)
Study: 15681523
Drug: Capecitabine plus
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine plus Bevacizumab (15 mg/kg)
Study: 1663853
Drug: EPO to
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO to achieve a hemoglobin of 95-110 g/L
Study: 1663853
Drug: EPO to
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO to achieve a hemoglobin of 115-130 g/L
Study: 1663853
Drug: EPO therapy
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO therapy (both dosages)
Study: 31694684
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine with paravertebral saline
Study: 31694684
Drug: Paravertebral lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paravertebral lidocaine with intravenous saline
Study: 31694684
Drug: Intravenous remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous remifentanil with paravertebral saline
Study: 19833260
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg, followed by 80 mg
Study: 19833260
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg, followed by 80 mg
Study: 19833260
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg, followed by 40 mg
Study: 19833260
Drug: Gene-dose effect
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Gene-dose effect
Study: 17537739
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment by hospital and primary care staff
Study: 11519773
Drug: Micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized progesterone (MP) 200 mg
Study: 11519773
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 5 mg
Study: 8010466
Drug: Late administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late administration of epidural analgesia (after 5 cm dilation) with prior intravenous nalbuphine (10 mg)
Study: 2686320
Drug: Sinestrol 1
Normalized name: dienestrol 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinestrol 1 mg orally twice a day for 3 weeks
Study: 28855417
Drug: Methionine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine intake (0, 5, 10, 15, 25, and 35 mg · kg‐1 · d‐1) with no Cys in the diet
Study: 28855417
Drug: Methionine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine intake (0, 2.5, 5, 7.5, 10, and 15 mg · kg‐1 · d‐1) with 21 mg · kg‐1 · d‐1 Cys
Study: 26860015
Drug: Bupivacaine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (1 mg/kg)
Study: 19505304
Drug: ASAQ orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASAQ orally once daily (ASAQ1)
Study: 19505304
Drug: ASAQ twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASAQ twice daily (ASAQ2)
Study: 19505304
Drug: Artemether +
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artemether + lumefantrine (AL) twice daily
Study: 15510758
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation of ferrous sulfate (200 mg) for 2 months
Study: 15510758
Drug: Weekly supplementation
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly supplementation of ferrous sulfate (200 mg) for 2 months
Study: 2190251
Drug: Methylphenidate infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate infusion
Study: 29806872
Drug: XR-NTX (380
Approvals — FDA: no, EMA: no, PMDA: no
Description: XR-NTX (380 mg intramuscular injections every fourth week)
Study: 24247300
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (2 μg/kg/min)
Study: 24247300
Drug: Low-dose nesiritide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose nesiritide (0.005 μg/kg/min without bolus)
Study: 21173349
Drug: Mechanical valve
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical valve replacement with optimal self-management anticoagulation therapy
Study: 18158199
Drug: Betamethasone oral
Normalized name: betamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone oral mini-pulse (OMP) therapy (5 mg orally on 2 consecutive days per week for 3 months)
Study: 18158199
Drug: Topical triamcinolone
Normalized name: triamcinolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical triamcinolone acetonide (0.1%) paste (applied thrice daily for 3 months)
Study: 10972608
Drug: etomidate, 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: etomidate, 0.2 mg/kg (intravenous group)
Study: 1532760
Drug: General practitioner
Approvals — FDA: no, EMA: no, PMDA: no
Description: General practitioner treatment
Study: 22219405
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment, 94 patients)
Study: 20591399
Drug: ranibizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranibizumab (0.5 mg/0.05 mL)
Study: 11898244
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of medications (control)
Study: 8814094
Drug: 3 years
Normalized name: NanoVM 1-3 years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 years treatment
Study: 8814094
Drug: 1 year
Normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 year treatment
Study: 6703855
Drug: Amitriptyline (N
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (N = 5) after abrupt cessation of therapy
Study: 6703855
Drug: Desipramine after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine after abrupt cessation of therapy
Study: 31273750
Drug: Experimental agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental agent with adaptive randomization and dose-schedule regimes
Study: 27440189
Drug: Web-based Acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based Acceptance and Commitment Therapy (ACT)
Study: 25433006
Drug: Temocillin administered
Normalized name: temocillin
DrugBank: Temocillin (DB12343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocillin administered three times daily (6 g daily)
Study: 25433006
Drug: Temocillin administered
Normalized name: temocillin
DrugBank: Temocillin (DB12343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocillin administered by continuous infusion (6 g daily)
Study: 25433006
Drug: Temocillin administered
Normalized name: temocillin
DrugBank: Temocillin (DB12343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocillin administered by continuous infusion (750 mg daily) in patients undergoing CVVH
Study: 19296044
Drug: MBP group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBP group (40 mg MBP for 8 months)
Study: 15534479
Drug: Contact-topical anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contact-topical anesthesia
Study: 8145904
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (saline placebo)
Study: 26939320
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional western medicine)
Study: 22998456
Drug: Chlorhexidine 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine 1% gel
Study: 20926135
Drug: Triamcinolone treatment
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone treatment for CRVO
Study: 19735519
Drug: Juvéderm injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juvéderm injectable gel with lidocaine (JUV + L)
Study: 19735519
Drug: Juvéderm injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juvéderm injectable gel without lidocaine (JUV)
Study: 8173183
Drug: Responders to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responders to therapy
Study: 8173183
Drug: Non-responders to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-responders to therapy
Study: 30685500
Drug: Ibuprofen advice
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen advice
Study: 20809991
Drug: COMET +
Normalized name: Cometriq
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: COMET + regular therapy
Study: 20809991
Drug: Regular therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular therapy only
Study: 6716644
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (3 mg in 1.7 ml physiologic saline solution) administered through the epidural catheter.
Study: 31034184
Drug: Liraglutide (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (up to 1.8 mg per day)
Study: 24824118
Drug: LDT monotherapy
Normalized name: LDT
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: LDT monotherapy (600 mg orally, once daily)